Two new anticoagulants: Dabigatran and Rivaroxaban Their influence on coagulation assays;Deux nouveaux anticoagulants: Dabigatran et Rivaroxaban Leur impact sur les examens de coagulation

Bio Tribune Magazine

Volumn 38, Issue 1, 2011, Pages 16-21

  Samama, M Michel ^a,b   Guinet, C ^a   Le Flem, L ^a  

^a Laboratoire Biomnis   (France)

^b HÔTEL DIEU   (France)

Author keywords

Calibrated Plasmas; Coagulation assays; Dabigatran; Rivaroxaban

Indexed keywords

EID: 80052639558     PISSN: 17729416     EISSN: 1951655X     Source Type: Journal    
DOI: 10.1007/s11834-011-0044-x     Document Type: Article

References (18)

1. Samama MM, Conard J, Horellou MH, et al. (2010) Deux nouveaux anticoagulants disponibles en 2010 - Dabigatran Etexilate et Rivaroxaban: progrès attendus - problèmes posés. Ann Pharm Fr 68: 359-369.
2. Palareti G, Leali N, Coccheri S, et al. (1997) Hemorrhagic complications of oral anticoagulant therapy: results of a prospective multicenter study ISCOAT (Italian Study on Complications of Oral Anticoagulant Therapy). G Ital Cardiol 27: 231-243.
3. Weitz JI, Hirsh J, Samama MM, American College of Chest Physicians (2008) New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133: 234S-256S.
4. Duggan ST, Scott LJ, Plosker GL (2009) Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. Drugs 69: 1829-1851.
5. van Ryn J, Stangier J, Haertter S, et al. (2010) Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103: 1116-1127.
6. Samama MM, Martinoli JL, LeFlem L, et al. (2010) Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 103: 815-825.
7. Samama MM, Guinet C (2011) Review: Laboratory assessment of new anticoagulants. Clin Chem Lab Med 49: 761-772.
8. Tripodi A, Chantarangkul V, Guinet C, Samama MM (2011) The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost 9: 226-228.
9. Lindhoff-Last E, Samama MM, Ortel TL, et al. (2010) Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 32: 673-679.
10. Merriman E, Kaplan Z, Butler J, et al. (2011) Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost 105: 385-386.
11. Depasse F, Gerotziafas GT, Busson J, et al. (2004) Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity. J Thromb Haemost 2: 346-348.
12. Samama MM, Amiral J, Guinet C, et al. (2010) An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost 104: 1078-1079.
13. Samama MM (2011) Interindividual variability of in vitro response to anticoagulants. Thromb Res 127: 1.
14. Wong PC, Jiang X (2010) Apixaban, a direct factor Xa inhibitor, inhibits gissue-factor induced human platelet aggregation in vitro: Comparison whth direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost 104: 302-310.
15. Freyburger G, Macouillard G, Labrouche S, Sztark F (2011) Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 127: 457-465.
16. Haas S (2010) Facts and artefacts of coagulation assays for factor Xa inhibitors. Thromb Haemost 103: 686-688.
17. Mueck W, Borris LC, Dahl OE, et al. (2008) Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 100: 453-461.
18. Mueck W, Eriksson BI, Bauer KA, et al. (2008) Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 47: 203-216.